LivaNova wins FDA PMA for aura6000 sleep apnea device

CURRENT BRIEF VERSION: LivaNova said the US Food and Drug Administration has granted premarket approval for its aura6000 System, an implantable hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea who have failed, can’t tolerate, or aren’t eligible for standard therapies such as positive airway pressure, oral appliances, or pharmacotherapy. FDA records show the PMA decision was made on March 18, 2026, for patients with an apnea-hypopnea index of 15 to 65. LivaNova is positioning aura6000 as the first and only US-approved hypoglossal nerve stimulation therapy without a complete concentric collapse contraindication or warning, and says a next-generation MRI-compatible version is expected in the first half of 2027, pending a supplement review. (accessdata.fda.gov)

Why it matters: For veterinary professionals, this is a human medtech regulatory story rather than a companion animal care development, but it’s notable as another example of the FDA opening the door to a more tailored neurostimulation approach in a crowded sleep apnea market. The approval was supported by LivaNova’s OSPREY trial, which previously met primary safety and efficacy endpoints, with six-month data showing a 66.2% median reduction in apnea-hypopnea index and 12-month top-line data showing a 65% responder rate and a 68% median AHI reduction. It also adds competitive pressure in sleep-device reimbursement, referral, and specialty pathway discussions, especially because FDA-cleared labeling appears broader on airway-collapse language than older hypoglossal stimulation systems. More broadly, it fits a wider FDA pattern in neuromodulation: the agency has also recently granted breakthrough device designation to Nia Therapeutics’ fully implantable closed-loop Smart Neurostimulation System for episodic memory loss after traumatic brain injury, underscoring continued regulatory openness to more targeted, indication-specific neurostimulation platforms. (investor.livanova.com)

What to watch: Watch for publication of fuller post-approval data, payer coverage decisions, and FDA review of the MRI-compatible supplement ahead of LivaNova’s planned first-half 2027 launch. In the broader neuromodulation space, Nia has said it plans to file an investigational device exemption application in 2026 after reporting a 19% recall improvement in a sham-controlled study, so that program is another signpost for how FDA may handle next-wave implantable neurostimulation technologies. (markets.financialcontent.com)